#	Pagina
attuale pagina	/open-h2020/projects/226272/index.html
-1	/open-h2020/per-topic/lit/list/index.html
-2	/open-consip/fornitori/2019/profilo-05965720963/index.html
-3	/open-consip/fornitori/2020/profilo-05366960010/index.html
-4	/open-h2020/projects/206067/index.html
-5	/open-consip/fornitori/2015/profilo-01472410164/index.html
-6	/open-consip/fornitori/2015/profilo-03929120164/index.html
-7	/open-h2020/projects/207609/deliverables.html
-8	/open-h2020/projects/195943/index.html
-9	/open-h2020/projects/218165/index.html
-10	/open-h2020/projects/211940/index.html

Opendata, web and dolomites

MEPHOS SIGNED

Shaping the Mechano-Pharmacological properties of Microparticles and Extracellular Vesicles for the Treatment of Osteoarthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

MEPHOS project word cloud

Explore the words cloud of the MEPHOS project. It provides you a very rough idea of what is the project "MEPHOS" about.

curing pain market clinically fluid 3 scientists 1 ambition metalloproteinase polymeric stem pharmacological bridge intersectoral single extracellular technologies realizing biological course halt subchondral chronic vitro academic bone risk small culture fabrication microplates sophisticated mephos rationally training obesity glycoproteins symptoms joint simultaneously societal adults options upls oa translational translation predicted sustainably hydrogel models characterization weeks vesicles inhibitors replacement sole mechanical stanford inclusion 2026 interdisciplinary clinical context rising consequently continues instil older deposition option molecules aging tissue regeneration cartilage action industrial trauma million osteoarthritis documents degeneration upl articular burden gender treatment hit biologicals chemokine viscoelastic boundaries clinic modulating strategy people cell disability release spark secondments geometry assays approved rational synovial disease 2016 match billion preclinical ultimately sme

Project "MEPHOS" data sheet

The following table provides information about the project.

Coordinator	FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA Organization address address: VIA MOREGO 30 city: GENOVA postcode: 16163 website: www.iit.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	952˙200 €
EC max contribution	864˙800 € (91%)
Programme	1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
Code Call	H2020-MSCA-RISE-2019
Funding Scheme	MSCA-RISE
Starting year	2020
Duration (year-month-day)	from 2020-04-01 to 2024-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA Organization address address: VIA MOREGO 30 city: GENOVA postcode: 16163 website: www.iit.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (GENOVA)	coordinator	312˙800.00
2	UNIVERSIDAD DE NAVARRA UNIVERSIDAD DE NAVARRA Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL city: PAMPLONA postcode: 31080 website: www.unav.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (PAMPLONA)	participant	253˙000.00
3	UNIVERSIDADE DO MINHO UNIVERSIDADE DO MINHO Organization address address: LARGO DO PACO city: BRAGA postcode: 4704 553 website: www.uminho.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (BRAGA)	participant	225˙400.00
4	LIPOCURE LTD LIPOCURE LTD Organization address address: HADASSAH EIN KEREM CAMPUS BUILDING JERUSALEM BIOTECHNOLOGY PARK city: JERUSALEM postcode: 91120 website: www.lipocurerx.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (JERUSALEM)	participant	73˙600.00
5	BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Organization address address: SERRA MALL 450 city: STANFORD postcode: 94305 2004 website: www.stanford.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (STANFORD)	partner	0.00
6	THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Organization address address: "AIRPORT DRIVE 104 SUITE 2200 CB #1350" city: CHAPEL HILL postcode: 27599 website: www.unc.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (CHAPEL HILL)	partner	0.00
7	University of Arkansas University of Arkansas Organization address address: Ozark Hall, 1 University of Arkansas 120 city: Fayetteville postcode: 72701 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (Fayetteville)	partner	0.00
8	VANDERBILT UNIVERSITY VANDERBILT UNIVERSITY Organization address address: WEST END AVENUE 2201 city: NASHVILLE TENESSEE postcode: 37235 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (NASHVILLE TENESSEE)	partner	0.00

Map

Project objective

Osteoarthritis (OA) is a chronic disease involving the degeneration of articular cartilage and subchondral bone. It represents the single most common cause of disability in older adults. Being aging, obesity, trauma and gender risk factors for OA, its societal burden is rapidly rising. Across EU, over 40 million people are affected by OA. Current treatment options aim at modulating the symptoms rather than curing this chronic disease. Consequently, joint replacement continues to be ultimately the sole option. In this context, MEPHOS aims at realizing an integrated strategy for OA treatment based on the intra-articular deposition of hydrogel, polymeric microplates (uPLs) that could simultaneously provide a long-term pharmacological action and mechanical support. To this end, the uPL geometry and mechanical properties will be rationally selected to match the viscoelastic behaviour of cartilage and synovial fluid. Over the course of several weeks, uPLs will sustainably release clinically-approved molecules for pain management and novel small molecules and biologicals; including chemokine and metalloproteinase inhibitors to halt tissue degeneration; glycoproteins, growth factors and stem cell-derived extracellular vesicles to favour tissue regeneration. MEPHOS involves three EU Academic Institutions and a SME for uPL fabrication, and four US Academic Institutions for uPL biological and preclinical characterization. Through interdisciplinary and intersectoral secondments, this project will support the training of EU scientists on sophisticated in-vitro assays and three different preclinical OA models; foster the rational development of uPLs; and instil a translational research culture to bridge preclinical-clinical boundaries. The inclusion of a SME and the Stanford SPARK Translation program documents MEPHOS ambition to develop technologies that could hit the clinic and an industrial market, which is predicted to growth from $1.6 billion in 2016 to $3.5 billion by 2026.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEPHOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEPHOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

MEGA (2019)

Heavy metal free emitters for new-generation light sources

Read More

FUNGLASS (2019)

FUNctional GLASS

Read More

aiD (2019)

aRTIFICIAL iNTELLIGENCE for the Deaf

Read More